Table 2.
Association between objective response and clinical factors or cytokines in plasma by univariate analysis.
| Factor | Median | Odds Ratio (95% CI) | P |
|---|---|---|---|
| Age (years) | 58.3 | 1.129 (0.987–1.291) | 0.076 |
| Gender (Male vs. Female) | NA | 0.417 (0.059–2.946) | 0.38 |
| Smoking (Never vs. Ever) | NA | 1.5 (0.251–8.977) | 0.657 |
| Pathology (ADC vs. SCC) | NA | 2.222 (0.402–12.285) | 0.36 |
| Stage* (IIB vs. IIIA vs. IIIB) |
NA | 0.371 (0.084–1.638) | 0.191 |
| EGFR mutation (wildtype vs. mutant) |
NA | 0.000 (NA) | 0.999 |
| Induction chemotherapy (No vs. Yes) |
NA | 0.909 (0.129–6.396) | 0.924 |
| CCL5 (ng/ml) | 14.863 | 1.051 (0.998–1.107) | 0.062 |
| CXCL3 | 314.12 | 1.004 (0.999–1.008) | 0.096 |
| Eotaxin | 139.09 | 1.005 (0.992–019) | 0.445 |
| EPO | 15.455 | 1.042 (0.956–1.136) | 0.345 |
| FLT3L | 175.11 | 1 (0.994–1.005) | 0.942 |
| G-CSF | 23.59 | 0.984 (0.954–1.015) | 0.321 |
| GM-CSF | 0.18 | 0.307 (0.000–3465.908) | 0.804 |
| ICAM-1 (ng/ml) | 553.397 | 0.997 (0.995–1.000) | 0.03 |
| IFN-γ | 25.36 | 0.963 (0.928–0.998) | 0.038 |
| IL-1α | 0.51 | 1.084 (0.677–1.736) | 0.737 |
| IL-1β | 0.2 | 1.533 (0.007–350.442) | 0.878 |
| IL-10 | 1.3 | 1.378 (0.056–33.828) | 0.844 |
| IL-12p70 | 40.9 | 0.933 (0.804–1.083) | 0.362 |
| IL-13 | 3.2 | 1.421 (1.039–1.941) | 0.028 |
| IL-2 | 5.7 | 0.496 (0.155–1.593) | 0.239 |
| IL-6 | 1.73 | 1.114 (0.832–1.491) | 0.469 |
| IL-8 | 4.12 | 1.507 (0.964–2.355) | 0.072 |
| IP-10 | 414.65 | 1.002 (0.997–1.006) | 0.474 |
| M-CSF | 50.11 | 0.993 (0.971–1.016) | 0.57 |
| sPD-L1 | 68.27 | 0.997 (0.995–1.000) | 0.042 |
| TNF-α | 4.59 | 2.985 (1.230–7.242) | 0.016 |
| TPO | 28.54 | 0.999 (0.994–1.004) | 0.661 |
| TRAIL | 31.57 | 1.007 (0.971–1.044) | 0.702 |
| VEGF | 16.1 | 1.061 (0.987–1.141) | 0.108 |
| WNT3A | 0.751 | 0.641 (0.172–2.396) | 0.509 |
The unit of the cytokines is pg/ml if not otherwise specified. Cytokines with P<0.1 are shown in bold.
*According to American Joint Commission on Cancer (AJCC) staging system 7th edition.